The Highs and Lows of 2017 – Cardiovascular, Metabolic, Renal, and Hematologic Diseases DRG cardiovascular, metabolic, renal, and hematologic (CMRH) disease experts have compiled their top ten market events in 2017. Events run the...
In DRG Blog/ January, 2018 Hyperkalemia Market Hits Over $2 Billion in Sales Hyperkalemia, elevated serum potassium, is a potentially life-threatening complication caused by a disruption of potassium homeostasis within the...
In DRG Blog/ December, 2017 Implications of Cardiovascular Benefit for Emerging Therapies in Diabetic Nephropathy Results from phase III clinical trials for diabetic nephropathy (DN), also known as diabetic kidney disease, are eagerly anticipated by the health...
In DRG Blog/ June, 2017 Gene Therapy: Clinical Promise Meets Sticker Shock Gene therapy is among the most promising trends in pharma, but the accompanying price tag has given some sticker shock that threatens to limit...
In DRG Blog, Drug Watch/ May, 2017 What Will Become of the Pragmatic Clinical Trial? The role of pragmatic clinical trials, or trials able to evaluate effectiveness of interventions in real world clinical practice, has been...
In DRG Blog, Drug Watch/ May, 2017 Bypassing Regulatory Hurdles for Faster Access to New Drugs?... Potential Disaster! Earlier this month saw President Trump call for an overhaul of the FDA and the way it approves drugs, in particular accelerating the drug approval...
In DRG Blog, Drug Watch/ March, 2017 Hyperkalemia talk draws a crowd at National Kidney Foundation’s spring clinical conference The hyperkalemia (HK) symposium at the spring National Kidney Foundation conference in Boston was a popular event. On Thursday April 28th, hundreds...
In DRG Blog, Drug Watch/ May, 2016 Hope at last! Activity in the Diabetic Nephropathy pipeline According to primary research conducted by DRG, Diabetic Nephropathy (DN) is considered the nephrology disease with the greatest unmet need for new...
In DRG Blog, Drug Watch/ December, 2015 
